Pharmacokinetic and pharmacodynamic analysis of 5-aza-2’-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy
<p>Abstract</p> <p>5-Aza-2′-deoxycytidine (5-AZA-CdR, decitabine), an epigenetic drug that inhibits DNA methylation, is currently used to treat myelodysplastic syndrome (MDS), and is under investigation for treating acute myeloid leukemia (AML) and other malignancies. 5-AZA-CdR can reactivate tumor...
Na minha lista:
| Principais autores: | , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BMC
2013-02-01
|
| Serier: | Clinical Epigenetics |
| Fag: | |
| Online adgang: | http://www.clinicalepigeneticsjournal.com/content/5/1/3 |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|
